Optimized Apamin-Mediated Nano-Lipidic Carrier Potentially Enhances the Cytotoxicity of Ellagic Acid against Human Breast Cancer Cells

Badr-Eldin, Shaimaa M.; Aldawsari, Hibah M; Fahmy, Usama A.; Ahmed, Osama A. A.; Alhakamy, Nabil A.; Al-Hejaili, Omar D; Alhassan, Alhanoof A; Ammari, Ghadeer A; Alhazmi, Shouq I; Alawadi, Raghad M; Bakhaidar, Rana B.; Alamoudi, Abdulmohsin J.; Neamatallah, Thikryat; Tima, Singkome

doi:10.3390/ijms23169440

Cited by 7 publications

(10 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Doxil, the first US Food and Drug Administration (FDA)-approved chemotherapeutic nanosystem to be used therapeutically, contains doxorubicin (DOX). The PEGylated DOX liposomal formulation extends circulation time and prevents premature removal of the nanoformulation . For dual targeting, i.e.…”

Section: Therapeutic Interventions Involving Nanocarriers For Managem...mentioning

confidence: 99%

“…Flow cytometric tests verified the improved cell penetration of the NLCs against the BT-474 cell line . Ellagic acid (EGA) is commonly used to prevent and treat cancer . A plethora of researchers have reported that surface-functionalized nanocarriers have been evaluated in tumor-targeted delivery of anticancer drugs .…”

Section: Therapeutic Interventions Involving Nanocarriers For Managem...mentioning

confidence: 99%

“…Furthermore, tumor necrosis factor-α (TNF-α) expression was elevated. In contrast, nuclear factor κ-light-chain-enhancer of activated B cells (NF-κB) activity was reduced, which supported the considerable induction of apoptosis by functionalized EGF-NLCs . Therefore, functionalized EGA-NLCs have been successfully proposed as effective lipidic nanocarriers in managing BC.…”

Section: Therapeutic Interventions Involving Nanocarriers For Managem...mentioning

confidence: 99%

“…The PEGylated DOX liposomal formulation extends circulation time and prevents premature removal of the nanoformulation. 33 For dual targeting, i.e. , bone cancer and BC, Zhao and associates developed paclitaxel (PTX)-loaded liposomes.…”

Section: Therapeutic Interventions Involving Nanocarriers For Managem...mentioning

confidence: 99%

“… 64 Ellagic acid (EGA) is commonly used to prevent and treat cancer. 33 A plethora of researchers have reported that surface-functionalized nanocarriers have been evaluated in tumor-targeted delivery of anticancer drugs. 33 The researcher who developed the apigenin-functionalized EGA-loaded NLCs demonstrated a substantial cytotoxic impact, with an IC 50 value of 5.472 μg/mL above that of the free drug reported at 9.09 μg/mL.…”

Section: Therapeutic Interventions Involving Nanocarriers For Managem...mentioning

confidence: 99%

See 4 more Smart Citations

Nanomedicine-Based Drug-Targeting in Breast Cancer: Pharmacokinetics, Clinical Progress, and Challenges

Rahman,

Afzal,

Ullah

et al. 2023

ACS Omega

View full text Add to dashboard Cite

Breast cancer (BC) is a malignant neoplasm that begins in the breast tissue. After skin cancer, BC is the second most common type of cancer in women. At the end of 2040, the number of newly diagnosed BC cases is projected to increase by over 40%, reaching approximately 3 million worldwide annually. The hormonal and chemotherapeutic approaches based on conventional formulations have inappropriate therapeutic effects and suboptimal pharmacokinetic responses with nonspecific targeting actions. To overcome such issues, the use of nanomedicines, including liposomes, nanoparticles, micelles, hybrid nanoparticles, etc., has gained wider attention in the treatment of BC. Smaller dimensional nanomedicine (especially 50–200 nm) exhibited improved in vivo effectiveness, such as better tissue penetration and more effective tumor suppression through enhanced retention and permeation, as well as active targeting of the drug. Additionally, nanotechnology, which further extended and developed theranostic nanomedicine by incorporating diagnostic and imaging agents in one platform, has been applied to BC. Furthermore, hybrid and theranostic nanomedicine has also been explored for gene delivery as anticancer therapeutics in BC. Moreover, the nanocarriers’ size, shape, surface charge, chemical compositions, and surface area play an important role in the nanocarriers’ stability, cellular absorption, cytotoxicity, cellular uptake, and toxicity. Additionally, nanomedicine clinical translation for managing BC remains a slow process. However, a few cases are being used clinically, and their progress with the current challenges is addressed in this Review. Therefore, this Review extensively discusses recent advancements in nanomedicine and its clinical challenges in BC.

show abstract

Section: Therapeutic Interventions Involving Nanocarriers For Managem...mentioning

confidence: 99%

Section: Therapeutic Interventions Involving Nanocarriers For Managem...mentioning

confidence: 99%

Section: Therapeutic Interventions Involving Nanocarriers For Managem...mentioning

confidence: 99%

Section: Therapeutic Interventions Involving Nanocarriers For Managem...mentioning

confidence: 99%

Section: Therapeutic Interventions Involving Nanocarriers For Managem...mentioning

confidence: 99%

See 3 more Smart Citations

Nanomedicine-Based Drug-Targeting in Breast Cancer: Pharmacokinetics, Clinical Progress, and Challenges

Rahman,

Afzal,

Ullah

et al. 2023

ACS Omega

View full text Add to dashboard Cite

show abstract

A comprehensive review on Ellagic acid in breast cancer treatment: From cellular effects to molecular mechanisms of action

Golmohammadi,

Zamanian,

Jalal

et al. 2023

Food Science & Nutrition

View full text Add to dashboard Cite

Globally, breast cancer (BC) is the leading cause of cancer‐related deaths in women. Hence, developing a therapeutic plan to overcome the disease is crucial. Numerous factors such as endogenous hormones and environmental factors may play a role in the pathophysiology of BC. Regarding the multi‐modality treatment of BC, natural compounds like ellagic acid (EA) received has received increased interest in antitumor efficacy with lower adverse effects. Based on the results of this comprehensive review, EA has multiple effects on BC cells including (1) suppresses the growth of BC cells by arresting the cell cycle in the G0/G1 phase, (2) suppresses migration, invasion, and metastatic, (3) stimulates apoptosis in MCF‐7 cells via TGF‐β/Smad3 signaling axis, (4) inhibits CDK6 that is important in cell cycle regulation, (5) binds to ACTN4 and induces its degradation via the ubiquitin‐proteasome pathway, inducing decreased cell motility and invasion in BC cells, (6) inhibits the PI3K/AKT pathway, and (7) inhibits angiogenesis‐associated activities including proliferation (reduces VEGFR‐2 tyrosine kinase activity). In conclusion, EA exhibits anticancer activity through various molecular mechanisms that influence key cellular processes like apoptosis, cell cycle, angiogenesis, and metastasis in BC. However, further researches are essential to fully elucidate its molecular targets and implications for clinical applications.

show abstract

3,3’4-trimethoxy-4’-rutinosylellagic acid and its acetylated derivative: Antioxidant activity and antiproliferative effects on breast cancer cells and molecular docking study

Feunaing,

Tamfu,

Gbaweng

et al. 2024

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

Optimized Apamin-Mediated Nano-Lipidic Carrier Potentially Enhances the Cytotoxicity of Ellagic Acid against Human Breast Cancer Cells

Cited by 7 publications

References 69 publications

Nanomedicine-Based Drug-Targeting in Breast Cancer: Pharmacokinetics, Clinical Progress, and Challenges

Nanomedicine-Based Drug-Targeting in Breast Cancer: Pharmacokinetics, Clinical Progress, and Challenges

A comprehensive review on Ellagic acid in breast cancer treatment: From cellular effects to molecular mechanisms of action

3,3’4-trimethoxy-4’-rutinosylellagic acid and its acetylated derivative: Antioxidant activity and antiproliferative effects on breast cancer cells and molecular docking study

Contact Info

Product

Resources

About